Last mentioned: Mar 19, 2026
Q4 2025 Earnings Call
Management discussed clinical progress of Lomecel-B and financial outlook.
Capital Raise
Entry into a material definitive agreement for the sale of unregistered equity securities.
NASDAQ Compliance Notice
Longeveron received notice of failure to satisfy NASDAQ listing rules.
Longeveron Inc. (LGVN) reported Q4 2025 results, highlighting clinical advancements in its Lomecel-B cell therapy for rare pediatric heart conditions and Alzheimer's disease. Despite clinical momentum, the company is managing significant financial headwinds, including a recent NASDAQ compliance notice and a subsequent capital raise in March 2026.
The Q4 2025 earnings cycle for niche leaders like Citi Trends and Kaltura reveals a retail sector balancing cautious value-based consumption with aggressive digital video expansion. While value retailers navigate inflationary pressures on lower-income households, the infrastructure for shoppable video and edge-based logistics continues to see robust investment.
Kaltura reports Q4 2025 results as it deepens its footprint in healthcare video solutions, while Longeveron faces listing challenges despite clinical progress with its Lomecel-B therapy. The dual reports underscore the diverging paths of established Health IT infrastructure versus high-risk clinical stage biotechnology.